|
Patent landscape, scope, and claims: |
Scope and Claims Analysis for US Drug Patent 10,729,653 (Brivaracetam + β-Cyclodextrin Immediate-Release Film-Coated Tablets)
US Patent 10,729,653 is a composition-of-matter and formulation-scoped patent that claims an oral, film-coated, immediate-release tablet whose core particulate system contains brivaracetam complexed or otherwise formulated with β-cyclodextrin as a binder, plus sodium croscarmellose as disintegrant and lactose (monohydrate and/or anhydrous) as diluent, with fixed quantitative constraints. The claim set tightens infringement risk to tablets falling inside specific composition ratios (brivaracetam:β-cyclodextrin = 3.7:1) and β-cyclodextrin loading (1.0 to 8.16% of particle weight; water content 10 to 14% w/w for dependent claims), and it further constrains some embodiments to specific mg-per-tablet recipes and some embodiments to the placement of magnesium stearate in an “external phase.”
What is protected (in plain terms)
- Drug substance: brivaracetam.
- Binder/complexing excipient: β-cyclodextrin (water content and wt% constraints).
- Disintegrant: sodium croscarmellose (0.5 to 25% by weight of particles).
- Diluent system: lactose monohydrate and/or anhydrous lactose (with broad diluent wt% bounds and specific mg embodiments).
- Dosage form: film-coated, immediate-release tablet.
- Core ratio constraint: brivaracetam to β-cyclodextrin is 3.7:1 (in the particles).
- Two-phase formulation nuance: at least some claims specify magnesium stearate exists “in an external phase,” consistent with a coating/particulate-manufacturing or lubrication layering approach.
Highest-risk infringement features
- β-cyclodextrin present at the claimed wt% and ratio to brivaracetam.
- β-cyclodextrin water content (dependent claim 2): 10 to 14% w/w.
- Particle excipient system uses sodium croscarmellose and lactose (mono/anhydrous) in claimed ranges.
- Tablet is film-coated and immediate-release.
- Embodiments with explicit mg recipes (claims 3, 6, 7, 9-14) and magnesium stearate external phase (claims 9-11).
What patents protect brivaracetam oral immediate-release film-coated tablets using β-cyclodextrin?
The claims you provided indicate a formulation patent focused on the excipient system rather than a new brivaracetam polymorph or a method-of-treatment. In the US, formulation protection like this typically sits alongside (and is often downstream of) earlier drug-substance patents and earlier basic solid form patents.
How the claim language maps to likely patent “buckets”
1) Composition/formulation claims (active + excipients + quantitative constraints)
- Claim 1 is the central formulation claim, limiting infringement to tablets containing a particle system with:
- brivaracetam
- β-cyclodextrin as binder
- sodium croscarmellose as disintegrant
- lactose monohydrate and/or anhydrous lactose as diluent
- film-coated immediate-release tablet
- β-cyclodextrin wt% 1.0 to 8.16% of total particle weight
- brivaracetam:β-cyclodextrin wt ratio 3.7:1
2) Dependent excipient attribute claim (water content)
- Claim 2 adds a material-property constraint on β-cyclodextrin: water content 10 to 14% w/w.
3) Numerical embodiment claims (mg-per-tablet recipes)
- Claims 3, 6, 7 set out explicit per-tablet mg compositions for the particle portion.
4) Formulation boundary claims (range limits)
- Claim 4 disintegrant range: 0.5 to 25% by weight of particles.
- Claim 5 diluent range: 30-90% by weight of particles.
5) Multi-component explicit external phase lubrication embodiments
- Claims 9-11 describe an “external phase” for magnesium stearate and define specific additive masses including anhydrous lactose and magnesium stearate separated from the “particles” mass.
6) Additional explicit mg formulations
- Claims 12-14 define combinations where the lactose is shifted into particles and/or additives and quantify sodium croscarmellose and magnesium stearate.
Key implication for freedom-to-operate (FTO)
Even if a generic uses brivaracetam and β-cyclodextrin, infringement turns on (i) meeting the 3.7:1 ratio, (ii) matching β-cyclodextrin loading, (iii) meeting water content in the dependent scenario, and (iv) matching the claimed immediate-release film-coated tablet context with sodium croscarmellose/lactose excipient logic.
What is the scope of claim 1 of US 10,729,653 (ratio, wt% and excipient system)?
Claim 1 is the main claim and likely the broadest. It defines an oral pharmaceutical composition that is:
- Film-coated
- Immediate release
- A tablet having:
- particles + pharmaceutically acceptable additives
- particles consist of:
- brivaracetam
- binder: β-cyclodextrin
- disintegrant: sodium croscarmellose
- diluent consisting of lactose monohydrate, anhydrous lactose, or mixtures
- additives consist of:
- sodium croscarmellose
- anhydrous lactose
- magnesium stearate
- quantitative constraints:
- β-cyclodextrin is 1.0 to 8.16% of total particle weight
- weight ratio brivaracetam : β-cyclodextrin = 3.7 : 1
Literal elements that must be met for infringement
- Dosage form requirement: film-coated immediate-release tablet.
- Two-part structure: particles + additives (and the claim specifies what goes where).
- Particle composition: brivaracetam + β-cyclodextrin (binder) + sodium croscarmellose (disintegrant) + lactose diluent (mono/anhydrous).
- Additive composition: sodium croscarmellose + anhydrous lactose + magnesium stearate.
- β-cyclodextrin loading in particles: 1.0 to 8.16% (wt basis).
- Brivaracetam to β-cyclodextrin mass ratio: 3.7:1.
Practical constraint analysis of the ratio
The ratio 3.7:1 is unusually specific. It creates a narrow “composition line” in formulation space:
- If a product changes β-cyclodextrin content by even moderate amounts, the ratio shifts and can exit the literal scope of claim 1.
- Formulators typically adjust excipient loadings based on solubility and tablet mechanical properties, so the ratio constraint is a frequent design-around target.
How does dependent claim 2 constrain β-cyclodextrin water content (10–14% w/w)?
Claim 2 limits the composition of claim 1 by requiring:
- β-cyclodextrin has water content between 10 and 14% (w/w).
Why that matters for design-around
- β-cyclodextrin commonly occurs with variable hydration states depending on processing and supplier specifications.
- Water-content control can require procurement controls, drying steps, and QC release testing.
- For an entrant, even if β-cyclodextrin loading and ratio are correct, using a β-cyclodextrin grade outside the water-content window may avoid claim 2 but still risk claim 1 infringement (since claim 2 is dependent; claim 1 may still be asserted independently).
What do the mg-per-tablet embodiment claims (3, 6, 7, 9–14) cover and how do they narrow infringement?
These claims add “hard numerics” that can be easier to map to marketed strengths and formulation recipes.
Embodiments centered on particle composition (claims 3, 6, 7)
-
Claim 3 (10 mg brivaracetam strength embodiment):
- particles consist of:
- 10.00 mg brivaracetam
- 2.7 mg β-cyclodextrin
- 45 mg lactose monohydrate
- 2 mg sodium croscarmellose
-
Claim 6 (25 mg brivaracetam strength embodiment):
- 25.00 mg brivaracetam
- 6.75 mg β-cyclodextrin
- 48.50 mg lactose monohydrate
- 2.50 mg sodium croscarmellose
-
Claim 7 (50 mg brivaracetam strength embodiment):
- 50.00 mg brivaracetam
- 13.50 mg β-cyclodextrin
- 97.00 mg lactose monohydrate
- 5.00 mg sodium croscarmellose
These embodiments effectively lock in:
- a brivaracetam:β-cyclodextrin ratio consistent with 3.7:1 (as 10:2.7, 25:6.75, 50:13.5 all match 3.7037:1 approx),
- β-cyclodextrin loading consistent with the claimed range.
Range-based boundary claims (claims 4 and 5)
- Claim 4: disintegrant is 0.5 to 25% by weight of the particles.
- Claim 5: diluent is 30-90% by weight of the particles.
These are broad enough that many formulations using lactose as bulk and sodium croscarmellose as disintegrant may fall inside unless excipient balancing is extreme.
External-phase lubrication embodiments (claims 9–11)
These claims introduce explicit additive masses and characterize magnesium stearate as being in an “external phase.”
-
Claim 9 (10 mg brivaracetam):
- particles:
- 10.00 mg brivaracetam
- 2.70 mg β-cyclodextrin
- 45.00 mg lactose monohydrate
- 2.00 mg sodium croscarmellose
- additives (external phase):
- 2.00 mg sodium croscarmellose
- 45.10 mg anhydrous lactose
- 1.20 mg magnesium stearate
-
Claim 10 (25 mg brivaracetam):
- particles:
- 25.00 mg brivaracetam
- 6.75 mg β-cyclodextrin
- 48.50 mg lactose monohydrate
- 2.50 mg sodium croscarmellose
- additives:
- 2.50 mg sodium croscarmellose
- 48.25 mg anhydrous lactose
- 1.50 mg magnesium stearate
-
Claim 11 (50 mg brivaracetam):
- particles:
- 50.00 mg brivaracetam
- 13.50 mg β-cyclodextrin
- 97.00 mg lactose monohydrate
- 5.00 mg sodium croscarmellose
- additives:
- 5.00 mg sodium croscarmellose
- 96.50 mg anhydrous lactose
- 3.00 mg magnesium stearate
Particle vs additive split is a key narrowing lever
Claim 9–11 do not just specify total tablet composition; they constrain where the sodium croscarmellose and lactose appear (particles vs additives) and require magnesium stearate in the external phase. A generic that blends excipients differently (for example, incorporating all sodium croscarmellose in the particles or using different lubrication distribution) can potentially avoid these specific numerics even if it matches claim 1 more generally.
Additional explicit mg variants (claims 12–14)
-
Claim 12 (10 mg brivaracetam):
- particles include: 10.00 mg brivaracetam, 2.70 mg β-cyclodextrin, 45.00 mg lactose monohydrate, 4.00 mg sodium croscarmellose, and 45.10 mg anhydrous lactose
- additives: 1.20 mg magnesium stearate
-
Claim 13 (25 mg brivaracetam):
- particles include: 25.00 mg brivaracetam, 6.75 mg β-cyclodextrin, 48.50 mg lactose monohydrate, 5.00 mg sodium croscarmellose, and 48.25 mg anhydrous lactose
- additives: 1.50 mg magnesium stearate
-
Claim 14 (50 mg brivaracetam):
- particles include: 50.00 mg brivaracetam, 13.50 mg β-cyclodextrin, 97.00 mg lactose monohydrate, 10.00 mg sodium croscarmellose, and 96.50 mg anhydrous lactose
- additives: 3.00 mg magnesium stearate
These variants further constrain excipient partitioning and absolute mg amounts.
How strong is the patent estate for US 10,729,653 in the brivaracetam formulation space?
Based on claim structure alone, US 10,729,653’s strength is tied to the hard ratio and material attribute constraints:
- Claim 1’s 3.7:1 ratio and β-cyclodextrin wt% band are more restrictive than many formulation patents that only require “a cyclodextrin” or “a disintegrant” generally.
- Dependent claim 2’s β-cyclodextrin water content adds another technical hook that can be used in infringement theory or validity arguments (depending on prior art specificity).
- The mg-per-tablet embodiments show that the patentee mapped the formulation to specific dosage strengths and possibly to a commercial product format.
Patent “estate” strength, however, can’t be fully assessed here without the full patent family record (continuations/divisionals, related continuations, and earlier application priority). Your prompt does not provide the patent family members, filing/priority dates, prosecution history, or cited prior art, so only claim-scope strength can be assessed from the provided claim set.
What generic entry risks exist for brivaracetam immediate-release film-coated tablets under US 10,729,653?
Risk profile by formulation strategy
High risk
- Using β-cyclodextrin as binder in particles,
- Using sodium croscarmellose as disintegrant in particles,
- Using lactose mono/anhydrous with the claimed partitioning,
- Matching brivaracetam:β-cyclodextrin = 3.7:1 in the particle system,
- Producing film-coated immediate-release tablets.
Medium risk
- Matching excipient system but deviating from exact mg embodiments.
- Potentially avoiding specific mg claims (3, 6, 7, 9–14), but still triggering claim 1 if ratio and wt% constraints still match.
Lower risk
- Altering the ratio so brivaracetam:β-cyclodextrin is outside 3.7:1,
- Using β-cyclodextrin with water content outside 10–14% (only mitigates dependent claim 2, not claim 1),
- Changing excipient positioning and magnesium stearate distribution so it is not an “external phase” in the claimed manner (relevant mainly to claims 9–11).
Likely litigation focus (from claim structure)
- Claim 1 infringement theory would typically center on analytical confirmation of:
- β-cyclodextrin wt% in particles,
- brivaracetam:β-cyclodextrin ratio,
- excipient identity and role (binder vs disintegrant),
- tablet release profile (immediate release),
- film coating presence.
- Claim 2 theory would require β-cyclodextrin water content measurement.
When does US 10,729,653 lose exclusivity (patent expiration and regulatory exclusivity interactions)?
This cannot be completed from the provided prompt because it requires at minimum:
- the patent filing date, priority date, and whether term adjustment (PTA) applies,
- any terminal disclaimer,
- the status of FDA regulatory exclusivities tied to the reference listed drug (RLD) and whether later patents extend exclusivity.
No such metadata is included in your request.
What is the Orange Book status of brivaracetam products relevant to US 10,729,653?
Orange Book listing status depends on:
- the specific brivaracetam NDA and strength(s) tied to the tablet,
- whether US 10,729,653 is listed for those strengths and indications,
- listed patent type (P1/P2/P3/P4) and expiration dates.
Your prompt does not include the Orange Book entry or NDA number, so no accurate status can be provided.
What formulations are protected by US 10,729,653 beyond the specific mg embodiments?
Within the limits of claim 1 and dependent claims, the protected formulation space includes combinations that still satisfy:
- β-cyclodextrin is 1.0 to 8.16% of particle weight,
- brivaracetam:β-cyclodextrin is 3.7:1,
- sodium croscarmellose is present as disintegrant (and possibly also as additive),
- lactose diluent is present as mono and/or anhydrous,
- additives include sodium croscarmellose and magnesium stearate (and anhydrous lactose),
- tablet is film-coated immediate release.
The mg embodiments (claims 3, 6, 7, 9–14) are narrower datapoints inside that broader constrained region.
How does US 10,729,653 compare with typical brivaracetam solid oral dosage patents (cyclodextrin vs alternative strategies)?
Based on claim framing, this patent is closer to:
- specific cyclodextrin-based excipient architecture patents than
- method-of-use or device patents.
Typical competitor design-around strategies in similar cyclodextrin formulation spaces include:
- using a different cyclodextrin derivative or different complexation excipient,
- adjusting the cyclodextrin loading so brivaracetam:cyclodextrin ratio misses the claimed ratio,
- replacing sodium croscarmellose with another disintegrant (or pushing disintegrant outside the particle/additive framework),
- using sustained/extended release rather than immediate release,
- changing lubrication distribution so it does not match the “external phase” language.
Your claims explicitly require:
- immediate release,
- film-coated,
- sodium croscarmellose and lactose systems,
- β-cyclodextrin with a quantified ratio.
What patent litigation affects US 10,729,653 (Paragraph IV, settlements, or injunctions)?
No litigation docket information is provided in your prompt. Without the litigation case caption, court, parties, or filing details, a correct summary cannot be produced.
Key Takeaways
- US 10,729,653 is formulation-centric: it claims an oral, film-coated, immediate-release tablet with a particulate system containing brivaracetam + β-cyclodextrin (binder) + sodium croscarmellose (disintegrant) + lactose (mono/anhydrous).
- Claim 1 is dominated by hard constraints: β-cyclodextrin is 1.0 to 8.16% of particle weight and brivaracetam:β-cyclodextrin = 3.7:1.
- Dependent claim 2 adds a material-property gate: β-cyclodextrin water content must be 10–14% w/w.
- Claims 3, 6, 7, 9–14 lock specific dosage-strength recipes and, in claims 9–11, specify magnesium stearate in an external phase.
- Design-around risk turns on ratio and excipient partitioning, not just the presence of β-cyclodextrin.
FAQs
- Does using β-cyclodextrin in brivaracetam tablets automatically infringe US 10,729,653?
- What’s the most direct design-around: changing β-cyclodextrin water content or changing the brivaracetam:β-cyclodextrin ratio?
- How does the “external phase” magnesium stearate language change infringement analysis for generic reformulations?
- If a tablet meets the claim 1 excipient ratio but not the film-coated requirement, is it outside the claim?
- Do the mg-per-tablet embodiment claims (10/25/50 mg formats) create multiple infringement pathways even when claim 1 is avoided?
References (APA)
No external sources were provided or cited in your prompt; therefore no reference list can be generated.
More… ↓
⤷ Start Trial
|
